Ilmainen podcast
This Week in CardiologyPodcast by Medscape
Aloita maksuton kokeilu7 vrk maksutta, sitten 7,99 €/kuukausi
This podcast delivers Dr. John Mandrola’s summary and perspective on top news of the week that cardiologists can’t miss. This podcast is intended for US health professionals only.
Tätä podcastia voi kuunnella ilmaiseksi kaikilla podcast-soittimilla ja Podimo-sovelluksella ilman tilausta.
Kaikki jaksot
326 jaksotSep 13 2024 This Week in Cardiology
More from ESC: the SCOFF trial and fasting before cardiac cath, MATTERHORN, humbling data with AI, plus a reflection on the work of being a patient are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Fasting Before Cardiac Procedures
* The SCOFF Trial https://doi.org/10.1093/eurheartj/ehae573
II. MV repair for Functional MR
Large Trials Support Mitral Valve Repair in Heart Failure
* MATTERHORN https://www.nejm.org/doi/full/10.1056/NEJMoa2408739
III. AI in Medicine
* Rapidx AI Project https://healthtranslationsa.org.au/project/rapid-x-ai/
* PROTEUS Trial Rationale paper https://pubmed.ncbi.nlm.nih.gov/37192698/
IV. Time Toxicity
* Time Toxicity https://link.springer.com/article/10.1007/s00520-024-08844-1
* Thread X https://x.com/EnriqueSoto8/status/1833587144256065859
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
13. syysk. 2024 - 25 min
Sep 06 2024 This Week in Cardiology
Feedback on ABYSS and beta-blockers, more ESC recap, including SHAM-PVI, FINEARTS-HF, and RESHAPE HF2 trials are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Feedback on ABYSS
Setbacks After Stopping Beta-Blockers
https://www.medscape.com/viewarticle/setbacks-after-stopping-beta-blockers-2024a1000fv7
Beta-Blockers Post-MI? No for Me, Even After the ABYSS Trial
https://www.medscape.com/viewarticle/beta-blockers-post-mi-no-me-even-after-abyss-trial-2024a1000fva
* ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
* REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
* QOL paper REDUCE AMI https://doi.org/10.1093/ehjcvp/pvae062
* Atenolol ED paper 10.1016/j.ehj.2003.08.016
II. SHAM-PVI
* JAMA SHAM-PVI paper https://jamanetwork.com/journals/jama/article-abstract/2823283
* Gupta QOL paper https://pubmed.ncbi.nlm.nih.gov/33952593/
III. FINEARTS HF
Finerenone Benefits Heart Failure With Preserved EF
https://www.medscape.com/viewarticle/finerenone-benefits-heart-failure-preserved-ef-2024a1000fza
Topline Finerenone Results Point to Advance in Heart Failure
https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2
* FINEHEARTS -HF NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
* FIDELIO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
* FIGARO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2110956
* Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? https://doi.org/10.1016/j.jacc.2024.08.033
IV. RESHAPE HF
TEER in Functional MR: Data Deluge, but No Easy Answers
https://www.medscape.com/viewarticle/teer-functional-mr-data-deluge-no-easy-answers-2024a1000fvg
* Mitra FR https://www.nejm.org/doi/full/10.1056/NEJMoa1805374
* COAPT https://www.nejm.org/doi/full/10.1056/NEJMoa1806640
* RESHAPE- HF2 https://www.nejm.org/doi/full/10.1056/NEJMoa2314328
* RESHAPE Subgroup paper https://doi.org/10.1016/j.jacc.2024.08.027
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
06. syysk. 2024 - 30 min
Aug 30 2024 This Week in Cardiology
From ESC: post-MI beta blockers, a new therapy for ATTR-CM, holding RASi before non-cardiac surgery, good news in HFpEF, and an ESC preview are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ABYSS
* ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
* REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
II. ATTR -CM HELIOS B
Positive Top Line Results for Vutrisiran in Cardiac Amyloidosis
https://www.medscape.com/viewarticle/positive-top-line-results-vutrisiran-cardiac-amyloidosis-2024a1000cjj
* HELIOS A https://www.tandfonline.com/doi/full/10.1080/13506129.2022.2091985
* HELIOS B https://www.nejm.org/doi/full/10.1056/NEJMoa2409134
III. STOP or NOT Trial
* Observational Study Showing Benefits of Holding RASi https://doi.org/10.1097/ALN.0000000000001404
* STOP or NOT Protocol Paper -- https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-019-3247-1
* JAMA STOP or NOT https://jamanetwork.com/journals/jama/fullarticle/2823118
IV. GLP1a in HFpEF
The GLP-1 Agonist Semaglutide in HFpEF Cleared a Low Bar https://www.medscape.com/viewarticle/995872
* STEP-HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
* STEP-HFpEF-DM https://www.nejm.org/doi/full/10.1056/NEJMoa2313917
* SELECT https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
* FLOW https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
* Lancet Meta-analysis https://doi.org/10.1016/S0140-6736(24)01643-X
V. ESC Preview
Mandrola's Five Big Trials to Look for at ESC 2024
https://www.medscape.com/viewarticle/mandrolas-five-big-trials-look-esc-2024-2024a1000fkt
Topline Finerenone Results Point to Advance in Heart Failure
https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
30. elok. 2024 - 26 min
Aug 23 2024 This Week in Cardiology
Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Suicidal ideation with GLP-1
Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution
https://www.medscape.com/viewarticle/signal-suicidality-glp-1-ra-semaglutide-experts-urge-caution-2024a1000fa7
* Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality
*
* Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full
II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF
* PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021
* SOLVD https://www.nejm.org/doi/full/10.1056/NEJM199108013250501
* CONSENSUS trial https://www.nejm.org/doi/full/10.1056/NEJM198706043162301
* Meta-analysis of Low vs High Dose ACE/ARB https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956
* Meta-analysis of Sac/Val vs ARB/ACE Inhibitors https://link.springer.com/article/10.1007/s00228-024-03686-6
* PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508
III. CASTLE HTx Critical Appraisal
* Critical Appraisal of CASTLE HTx https://doi.org/10.1016/j.jacc.2024.06.020
* CASTLE HTx https://www.nejm.org/doi/10.1056/NEJMoa2306037
* CASTLE AF https://www.nejm.org/doi/full/10.1056/NEJMoa1707855
IV. More Data Suggesting Modest Benefits of the Primary Prevention ICD
* First and Recurrent ICD Shocks: JICE Paper from Denmark https://link.springer.com/article/10.1007/s10840-024-01873-0
* HF trialists https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 PROFID Trial https://profid-project.eu/
* DANISH https://www.nejm.org/doi/full/10.1056/NEJMoa1608029
* SCD-HeFT https://www.nejm.org/doi/full/10.1056/NEJMoa043399
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
23. elok. 2024 - 32 min
Aug 16 2024 This Week in Cardiology
Diuretic therapy in HFrEF, AF ablation, TACT 2 and the story of subgroups, and SGLT2 inhibitor underuse are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Diuretic Therapy in HF
* Dapa vs Metolazone Trial https://doi.org/10.1093/eurheartj/ehad341 ADVOR https://www.nejm.org/doi/10.1056/NEJMoa2203094
II. Rapid Medication Titration for Acute HF
* ACC Decision Pathway https://www.jacc.org/doi/10.1016/j.jacc.2024.06.002
III. SGLT2 Inhibitor Use in the US
* Shin and Colleagues; JACC https://www.sciencedirect.com/science/article/abs/pii/S0735109724076332
* Editorial https://doi.org/10.1016/j.jacc.2024.07.001
IV. AF Ablation: General Anesthesia vs Conscious Sedation
* Da Riis-Vestergaard and Colleagues https://doi.org/10.1093/europace/euae203
V. TACT 2 Published
* TACT 1 https://jamanetwork.com/journals/jama/fullarticle/1672238
* TACT 1 DM https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.113.000663
* TACT 2 https://jamanetwork.com/journals/jama/fullarticle/2822472
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
16. elok. 2024 - 29 min
Loistava design ja vihdoin on helppo löytää podcasteja, joista oikeasti tykkää
Kiva sovellus podcastien kuunteluun, ja sisältö on monipuolista ja kiinnostavaa
Todella kiva äppi, helppo käyttää ja paljon podcasteja, joita en tiennyt ennestään.
Saatavilla kaikkialla
Kuuntele Podimoa puhelimella, tabletilla, tietokoneella tai autossa!
Kokonainen maailma kuunneltavaa viihdettä
Tuhansia äänikirjoja ja yksinoikeuspodcasteja
Ei mainoksia
Kuuntelemalla Podimon sisältöä et tuhlaa aikaa mainosten kuuntelemiseen.
Tarjouksesi
Rajattomasti yksinoikeuspodcastien kuuntelua
Ei mainoksia
20 tuntia äänikirjoja / kk
Kokeilun jälkeen vain 7,99 € / kuukausi. Ei sitoutumista!